171 related articles for article (PubMed ID: 34667111)
21. Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy.
Garcia-Prada CD; Carmes L; Atis S; Parach A; Bertolet A; Jarlier M; Poty S; Garcia DS; Shin WG; Du Manoir S; Schuemann J; Tillement O; Lux F; Constanzo J; Pouget JP
J Nucl Med; 2023 Dec; 64(12):1956-1964. PubMed ID: 37857502
[TBL] [Abstract][Full Text] [Related]
22. Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy.
Membreno R; Keinänen OM; Cook BE; Tully KM; Fung KC; Lewis JS; Zeglis BM
Mol Pharm; 2019 May; 16(5):2259-2263. PubMed ID: 30912951
[TBL] [Abstract][Full Text] [Related]
23. Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies.
Boudousq V; Ricaud S; Garambois V; Bascoul-Mollevi C; Boutaleb S; Busson M; Quenet F; Colombo PE; Bardiès M; Kotzki PO; Navarro-Teulon I; Pèlegrin A; Pouget JP
J Nucl Med; 2010 Nov; 51(11):1748-55. PubMed ID: 20956481
[TBL] [Abstract][Full Text] [Related]
24. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
[TBL] [Abstract][Full Text] [Related]
25. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
26. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
Vallabhajosula S; Smith-Jones PM; Navarro V; Goldsmith SJ; Bander NH
Prostate; 2004 Feb; 58(2):145-55. PubMed ID: 14716739
[TBL] [Abstract][Full Text] [Related]
27. Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis.
Koppe MJ; Hendriks T; Boerman OC; Oyen WJ; Bleichrodt RP
J Nucl Med; 2006 Nov; 47(11):1867-74. PubMed ID: 17079821
[TBL] [Abstract][Full Text] [Related]
28. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
29. Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy.
Kinuya S; Li XF; Yokoyama K; Mori H; Shiba K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
Cancer Sci; 2003 Jul; 94(7):650-4. PubMed ID: 12841877
[TBL] [Abstract][Full Text] [Related]
30. Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.
Boudousq V; Bobyk L; Busson M; Garambois V; Jarlier M; Charalambatou P; Pèlegrin A; Paillas S; Chouin N; Quenet F; Maquaire P; Torgue J; Navarro-Teulon I; Pouget JP
PLoS One; 2013; 8(7):e69613. PubMed ID: 23922757
[TBL] [Abstract][Full Text] [Related]
31. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
Yao Z; Zhang M; Garmestani K; Axworthy DB; Mallett RW; Fritzberg AR; Theodore LJ; Plascjak PS; Eckelman WC; Waldmann TA; Pastan I; Paik CH; Brechbiel MW; Carrasquillo JA
Clin Cancer Res; 2004 May; 10(9):3137-46. PubMed ID: 15131055
[TBL] [Abstract][Full Text] [Related]
32. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.
van Rij CM; Lütje S; Frielink C; Sharkey RM; Goldenberg DM; Franssen GM; McBride WJ; Rossi EA; Oyen WJ; Boerman OC
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1377-83. PubMed ID: 23674207
[TBL] [Abstract][Full Text] [Related]
33.
Poty S; Mandleywala K; O'Neill E; Knight JC; Cornelissen B; Lewis JS
Theranostics; 2020; 10(13):5802-5814. PubMed ID: 32483420
[No Abstract] [Full Text] [Related]
34. A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.
Green DJ; Orgun NN; Jones JC; Hylarides MD; Pagel JM; Hamlin DK; Wilbur DS; Lin Y; Fisher DR; Kenoyer AL; Frayo SL; Gopal AK; Orozco JJ; Gooley TA; Wood BL; Bensinger WI; Press OW
Cancer Res; 2014 Feb; 74(4):1179-89. PubMed ID: 24371230
[TBL] [Abstract][Full Text] [Related]
35. Metal-Free Cycloaddition Chemistry Driven Pretargeted Radioimmunotherapy Using α-Particle Radiation.
Shah MA; Zhang X; Rossin R; Robillard MS; Fisher DR; Bueltmann T; Hoeben FJM; Quinn TP
Bioconjug Chem; 2017 Dec; 28(12):3007-3015. PubMed ID: 29129050
[TBL] [Abstract][Full Text] [Related]
36. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
Pagel JM; Matthews DC; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Gopal AK; Lin Y; Saganic L; Appelbaum FR; Press OW
Cancer Res; 2009 Jan; 69(1):185-92. PubMed ID: 19118002
[TBL] [Abstract][Full Text] [Related]
37. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
38. Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and
Orozco JJ; Kenoyer AL; Lin Y; O'Steen S; Guel R; Nartea ME; Hernandez AH; Hylarides MD; Fisher DR; Balkin ER; Hamlin DK; Wilbur DS; Orcutt KD; Wittrup KD; Green DJ; Gopal AK; Till BG; Sandmaier B; Press OW; Pagel JM
Mol Cancer Ther; 2020 Dec; 19(12):2575-2584. PubMed ID: 33082277
[TBL] [Abstract][Full Text] [Related]
39. Click-Mediated Pretargeted Radioimmunotherapy of Colorectal Carcinoma.
Membreno R; Cook BE; Fung K; Lewis JS; Zeglis BM
Mol Pharm; 2018 Apr; 15(4):1729-1734. PubMed ID: 29502416
[TBL] [Abstract][Full Text] [Related]
40. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).
Weiden PL; Breitz HB
Crit Rev Oncol Hematol; 2001 Oct; 40(1):37-51. PubMed ID: 11578915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
